PIPELINE
PIPELINE
Targeting What Others Won't, Advancing What Others Can't
Targeting What Others Won't, Advancing What Others Can't
VivaMed BioPharma’s pipeline includes over 50 active drug assets—ranging from new chemical entities to repurposed drugs—focused on areas of critical unmet need. We prioritize conditions with high clinical urgency, limited treatment options, and strong scientific rationale. Our AI-powered development model helps us identify promising opportunities earlier and accelerate them through the pipeline with less risk, lower cost, and faster timelines.
VivaMed BioPharma’s pipeline includes over 50 active drug assets—ranging from new chemical entities to repurposed drugs—focused on areas of critical unmet need. We prioritize conditions with high clinical urgency, limited treatment options, and strong scientific rationale. Our AI-powered development model helps us identify promising opportunities earlier and accelerate them through the pipeline with less risk, lower cost, and faster timelines.
THERAPEUTIC AREAS
THERAPEUTIC AREAS
Focused Where Impact Is Most Urgent
Focused Where Impact Is Most Urgent
We develop therapies across five high-priority categories—each chosen for its clinical relevance, unmet need, and potential for scalable innovation.
We develop therapies across five high-priority categories—each chosen for its clinical relevance, unmet need, and potential for scalable innovation.
DEVELOPMENT STRATEGY
DEVELOPMENT STRATEGY
A Smarter, Faster Pipeline Model
A Smarter, Faster Pipeline Model
Unlike traditional pipelines that rely on a single asset, our model diversifies risk by developing multiple compounds across therapeutic areas and stages. We accelerate development using AI to model toxicity, optimize dosage, and draft regulatory and IP filings. We also prioritize repurposed drugs and novel formulations—leveraging existing safety data to cut time and cost from development timelines.
Unlike traditional pipelines that rely on a single asset, our model diversifies risk by developing multiple compounds across therapeutic areas and stages. We accelerate development using AI to model toxicity, optimize dosage, and draft regulatory and IP filings. We also prioritize repurposed drugs and novel formulations—leveraging existing safety data to cut time and cost from development timelines.
50+ active drug assets in development
150+ licensed or developed to date
39 regulatory approvals supported
AI-assisted development, from ideation to IND
Pipeline includes both breakthrough therapies and best-in-class repurposed drugs
PIPELINE
From novel compounds to repurposed therapies, our pipeline is built for speed, scale, and relevance
Asset
Mechanism of Action
Class
Indication
Status
Asset
VM1974
Norepinephrine Reuptake Inhibitor (NRI)
Mechanism of Action
NCE
Class
Centralized Pain (Osteoarthritis)
Indication
Phase II
Status
Norepinephrine Reuptake Inhibitor (NRI)
NCE
Centralized Pain (Osteoarthritis)
Phase II
Asset
VM0102
Nicotinic Acetylcholine (nACh) Partial Agonist
Mechanism of Action
NCE
Class
Nociceptive Pain (Postoperative)
Indication
Preclinical
Status
VM0120
Asset
Nicotinic Acetylcholine (nACh) Partial Agonist
Mechanism of Action
NCE
Class
Neuropathic Pain
Indication
Preclinical
Status
VM2124
Asset
Cannabinoid Type 2 (CB1) Neutral Antagonist
Mechanism of Action
NCE
Class
Neuropathic Pain (Chemo Induced)
Indication
Phase I
Status
VM1710
Asset
Cannabinoid Type 2 (CB2) Agonist
Mechanism of Action
NCE
Class
Centralized Pain (Fibromyalgia)
Indication
Preclinical
Status
VM8156
Asset
Cannabinoid type 2 (CB2) Allosteric Modulator
Mechanism of Action
NCE
Class
Neuropathic Pain
Indication
Preclinical
Status
VM6128
Asset
N-methyl-D-aspartate (NMDA) Antagonist
Mechanism of Action
505(b)(2)
Class
Centralized Pain (Refractory to Tx)
Indication
Phase II
Status
VM0120
Asset
Nicotinic Acetylcholine (nACh) Agonist
Mechanism of Action
NCE
Class
Tobacco Use Disorder
Indication
Preclinical
Status
VM6527
Asset
Cannabinoid Type 1 (CB1) Neutral Antagonist
Mechanism of Action
NCE
Class
Opioid Use Disorder
Indication
Preclinical
Status
VM5100
Asset
Cannabinoid Broad Spectrum Modulator
Mechanism of Action
BDS
Class
Nutritional Supp. (OTC)
Indication
Research
Status
HC0007
Asset
Stilbenoid Broad Spectrum Modulator
Mechanism of Action
BDS
Class
Maj. Depressive Disorder
Indication
Research
Status
PS0101
Asset
Serotnin (5-HT) Partial Agonist
Mechanism of Action
BDS
Class
Post Traumatic Stress
Indication
Preclinical
Status
IB1899
Asset
NMDA, nACh Antagonist, KOR, 5-HT Agonist
Mechanism of Action
BDS
Class
Substance Use Disorder
Indication
Research
Status
TP3A66
Asset
TAAR 1 Agonist / GluR5 Kainate Antagonist
Mechanism of Action
505(b)(2)
Class
Stimulant Use Disorder
Indication
Phase II
Status
EN1273
Asset
NMDA Antagonist / Anti-Muscarinic
Mechanism of Action
505(b)(2)
Class
Opioid Use Disorder
Indication
Phase II
Status
VM1974
Norepinephrine Reuptake Inhibitor (NRI)
NCE
Centralized Pain (Osteoarthritis)
Phase II
VM0102
Nicotinic Acetylcholine (nACh) Partial Agonist
NCE
Nociceptive Pain (Postoperative)
Preclinical
VM0120
Nicotinic Acetylcholine (nACh) Partial Agonist
NCE
Neuropathic Pain
Preclinical
VM2124
Cannabinoid Type 2 (CB1) Neutral Antagonist
NCE
Neuropathic Pain (Chemo Induced)
Phase I
VM1710
Cannabinoid Type 2 (CB2) Agonist
NCE
Centralized Pain (Fibromyalgia)
Preclinical
VM8156
Cannabinoid type 2 (CB2) Allosteric Modulator
NCE
Neuropathic Pain
Preclinical
VM6128
N-methyl-D-aspartate (NMDA) Antagonist
505(b)(2)
Centralized Pain (Refractory to Tx)
Phase II
VM0120
Nicotinic Acetylcholine (nACh) Agonist
NCE
Tobacco Use Disorder
Preclinical
VM6527
Cannabinoid Type 1 (CB1) Neutral Antagonist
NCE
Opioid Use Disorder
Preclinical
VM5100
Cannabinoid Broad Spectrum Modulator
BDS
Nutritional Supp. (OTC)
Research
HC0007
Stilbenoid Broad Spectrum Modulator
BDS
Maj. Depressive Disorder
Research
PS0101
Serotnin (5-HT) Partial Agonist
BDS
Post Traumatic Stress
Preclinical
IB1899
NMDA, nACh Antagonist, KOR, 5-HT Agonist
BDS
Substance Use Disorder
Research
TP3A66
TAAR 1 Agonist / GluR5 Kainate Antagonist
505(b)(2)
Stimulant Use Disorder
Phase II
EN1273
NMDA Antagonist / Anti-Muscarinic
505(b)(2)
Opioid Use Disorder
Phase II
